4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/302% above fair value
$12.12−0.88 (-6.74%)
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
4D Molecular Therapeutics cash
Cash and short-term investments held at the end of each period.
4D Molecular Therapeutics's cash was $306.99M at Sep 30, 2026. For fiscal 2025 it was $514.00M, up 21.0% from the year before. The highest annual figure on record is $514.00M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $514.00M | +21.0% |
| FY2024 | Dec 31, 2024 | $424.88M | +47.4% |
| FY2023 | Dec 31, 2023 | $288.23M | +35.0% |
| FY2022 | Dec 31, 2022 | $213.55M | -13.8% |
| FY2021 | Dec 31, 2021 | $247.78M | -10.5% |
| FY2020 | Dec 31, 2020 | $276.73M | +457.3% |
| FY2019 | Dec 31, 2019 | $49.65M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $306.99M | +0.6% |
| Q2 FY2026 | Jun 30, 2026 | $361.33M | +23.2% |
| Q1 FY2026 | Mar 31, 2026 | $390.89M | +21.6% |
| Q4 FY2025 | Dec 31, 2025 | $514.00M | +21.0% |
| Q3 FY2025 | Sep 30, 2025 | $305.06M | -39.2% |
| Q2 FY2025 | Jun 30, 2025 | $293.23M | -45.9% |
| Q1 FY2025 | Mar 31, 2025 | $321.44M | -38.9% |
| Q4 FY2024 | Dec 31, 2024 | $424.88M | +47.4% |
| Q3 FY2024 | Sep 30, 2024 | $501.89M | +57.0% |
| Q2 FY2024 | Jun 30, 2024 | $541.95M | +74.6% |
| Q1 FY2024 | Mar 31, 2024 | $525.91M | +162.4% |
| Q4 FY2023 | Dec 31, 2023 | $288.23M | +35.0% |
| Q3 FY2023 | Sep 30, 2023 | $319.66M | +40.4% |
| Q2 FY2023 | Jun 30, 2023 | $310.34M | +28.7% |
| Q1 FY2023 | Mar 31, 2023 | $200.45M | -15.1% |
| Q4 FY2022 | Dec 31, 2022 | $213.55M | -13.8% |
| Q3 FY2022 | Sep 30, 2022 | $227.72M | +150.3% |
| Q2 FY2022 | Jun 30, 2022 | $241.09M | -1.1% |
| Q1 FY2022 | Mar 31, 2022 | $236.15M | -9.1% |
| Q4 FY2021 | Dec 31, 2021 | $247.78M | -10.5% |
| Q3 FY2021 | Sep 30, 2021 | $90.99M | +83.3% |
| Q2 FY2021 | Jun 30, 2021 | $243.74M | – |
| Q1 FY2021 | Mar 31, 2021 | $259.87M | – |
| Q4 FY2020 | Dec 31, 2020 | $276.73M | – |
| Q4 FY2019 | Dec 31, 2019 | $49.65M | – |
See a number that looks wrong?